AcuraStem Inc
http://acurastem.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From AcuraStem Inc
Finance Watch: Scion Life Sciences Launches With $310m Inaugural VC Fund
Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.
Takeda Uses AcuraStem Deal To Bolster Neuro Pipeline, Move Into ALS
Deal Snapshot: Looking to add to its neuroscience pipeline, Takeda acquires rights to the antisense candidate AS-202 from AcuraStem for development as a potential amyotrophic lateral sclerosis therapy.
Company Information
- Industry
- Biotechnology
- Diversified
- Pharmaceuticals
-
Pharmaceuticals
- Chiral Chemistry
-
Biotechnology
- Antisense, Oligonucleotides
- Drug Discovery Tools
- Large Molecule
- Liposomes
- Nanotechnology, Chips, etc.
- Pharmacogenetics-Pharmacogenomics
- Synthesis Technologies, Production Processes
- Transgenics
-
Large Molecule
- Antibodies
-
Drug Discovery Tools
- ADMET
- Bioinformatics
- Molecular Diversity
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice